Cargando…

Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests

High-throughput screening (HTS) is one of the newest techniques used in drug design and may be applied in biological and chemical sciences. This method, due to utilization of robots, detectors and software that regulate the whole process, enables a series of analyses of chemical compounds to be cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Szymański, Paweł, Markowicz, Magdalena, Mikiciuk-Olasik, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269696/
https://www.ncbi.nlm.nih.gov/pubmed/22312262
http://dx.doi.org/10.3390/ijms13010427
_version_ 1782222494986403840
author Szymański, Paweł
Markowicz, Magdalena
Mikiciuk-Olasik, Elżbieta
author_facet Szymański, Paweł
Markowicz, Magdalena
Mikiciuk-Olasik, Elżbieta
author_sort Szymański, Paweł
collection PubMed
description High-throughput screening (HTS) is one of the newest techniques used in drug design and may be applied in biological and chemical sciences. This method, due to utilization of robots, detectors and software that regulate the whole process, enables a series of analyses of chemical compounds to be conducted in a short time and the affinity of biological structures which is often related to toxicity to be defined. Since 2008 we have implemented the automation of this technique and as a consequence, the possibility to examine 100,000 compounds per day. The HTS method is more frequently utilized in conjunction with analytical techniques such as NMR or coupled methods e.g., LC-MS/MS. Series of studies enable the establishment of the rate of affinity for targets or the level of toxicity. Moreover, researches are conducted concerning conjugation of nanoparticles with drugs and the determination of the toxicity of such structures. For these purposes there are frequently used cell lines. Due to the miniaturization of all systems, it is possible to examine the compound’s toxicity having only 1–3 mg of this compound. Determination of cytotoxicity in this way leads to a significant decrease in the expenditure and to a reduction in the length of the study.
format Online
Article
Text
id pubmed-3269696
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-32696962012-02-06 Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests Szymański, Paweł Markowicz, Magdalena Mikiciuk-Olasik, Elżbieta Int J Mol Sci Review High-throughput screening (HTS) is one of the newest techniques used in drug design and may be applied in biological and chemical sciences. This method, due to utilization of robots, detectors and software that regulate the whole process, enables a series of analyses of chemical compounds to be conducted in a short time and the affinity of biological structures which is often related to toxicity to be defined. Since 2008 we have implemented the automation of this technique and as a consequence, the possibility to examine 100,000 compounds per day. The HTS method is more frequently utilized in conjunction with analytical techniques such as NMR or coupled methods e.g., LC-MS/MS. Series of studies enable the establishment of the rate of affinity for targets or the level of toxicity. Moreover, researches are conducted concerning conjugation of nanoparticles with drugs and the determination of the toxicity of such structures. For these purposes there are frequently used cell lines. Due to the miniaturization of all systems, it is possible to examine the compound’s toxicity having only 1–3 mg of this compound. Determination of cytotoxicity in this way leads to a significant decrease in the expenditure and to a reduction in the length of the study. Molecular Diversity Preservation International (MDPI) 2011-12-29 /pmc/articles/PMC3269696/ /pubmed/22312262 http://dx.doi.org/10.3390/ijms13010427 Text en © 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Szymański, Paweł
Markowicz, Magdalena
Mikiciuk-Olasik, Elżbieta
Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
title Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
title_full Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
title_fullStr Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
title_full_unstemmed Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
title_short Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
title_sort adaptation of high-throughput screening in drug discovery—toxicological screening tests
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269696/
https://www.ncbi.nlm.nih.gov/pubmed/22312262
http://dx.doi.org/10.3390/ijms13010427
work_keys_str_mv AT szymanskipaweł adaptationofhighthroughputscreeningindrugdiscoverytoxicologicalscreeningtests
AT markowiczmagdalena adaptationofhighthroughputscreeningindrugdiscoverytoxicologicalscreeningtests
AT mikiciukolasikelzbieta adaptationofhighthroughputscreeningindrugdiscoverytoxicologicalscreeningtests